Bank of New York Mellon
OPNT

Bank of New York Mellon’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Bank of New York Mellon’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17,796
Closed -$191K – 4584
2022
Q3 		$191K Buy
17,796
+117
+0.7% +$1.33K ﹤0.01% 4037
2022
Q2 		$212K Buy
+17,679
New +$285K ﹤0.01% 4030
2022
Q1 		– Sell
-7,803
Closed -$262K – 4725
2021
Q4 		$262K Buy
+7,803
New +$217K ﹤0.01% 4152

Other funds holding OPNT

WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NYLIM
New York Life Investment Management New York $14.3B AUM 34.42% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
RA
Ramius Advisors New York $95.2M AUM 7.33% 1-Year Est. Return

Bank of New York Mellon's OPNT Position: Q4 2022 in Review

Bank of New York Mellon sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q4 2022, closing a stake of 17,796 shares — an estimated $191K sold.

Bank of New York Mellon first reported a position in OPNT in Q4 2021 and held it in 3 quarters. The position peaked at $262K in Q4 2021. 37 funds tracked by Wall St. Rank hold OPNT as of Q4 2022.

  • Bank of New York Mellon reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 17,796 Opiant Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $191K.
  • Bank of New York Mellon first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Bank of New York Mellon's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $262K in Q4 2021.
  • 37 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Bank of New York Mellon's 13F filing for Q4 2022, filed 14 Feb 2023.